Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer

Medical Oncology

Volumn 24, Issue 4, 2007, Pages 431-435

  Yaman, Emel ^a   Uner, Aytug ^a   Er, Ozlem ^b   Coskun, Ugur ^a   Buyukberber, Suleyman ^a   Dikilitas, Mustafa ^b   Polat, Mevlude ^b   Yamac, Deniz ^a   Kaya, Ali Osman ^a   Yildiz, Ramazan ^a   Ozturk, Banu ^a   Benekli, Mustafa ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Metastatic colorectal cancer; Oxaliplatin Capecitabine

Indexed keywords

CAPECITABINE; OXALIPLATIN;

ADULT; AGED; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; FUNCTIONAL DISEASE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PARESTHESIA; PRIORITY JOURNAL; SENSORY NEUROPATHY; SURVIVAL RATE; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 36248973681     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-007-0035-7     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. De Gramont A, Figer A, Seymour M, et al. Leucovorin and Fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
3. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000;355:1041-7.
4. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001;19:2282-92.
5. Chang DZ, Abbruzzese JL. Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX. Clin Adv Hematol Oncol 2005;3:400-4.
6. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;3:205-16.
7. National Cancer Institute Common Toxicity Criteria (NCI-CTC) v2.0. http://www.ctep.info.nih.gov/reporting/ctc.html.
8. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-81.
9. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for metastatic with colorectal cancer. J Clin Oncol 2004;22:2084-91.
10. Shields AF, Zalupski MM, Marshall JL, Meropol NJ. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. Cancer 2004;100:531-7.
11. Hochster HS, Hart LL, Ramanathan RK, Hainsworth JD, Hedrick EE, Childs BH. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006:3510.
12. Martoni AA, Pinto C, Di Fabio F, et al. Capecitabine plus oxaliplatin (XELOX) versus protracted fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomized study (FOCA trial). Eur J Cancer 2006;42:3161-8.
13. Zeuli M, Nardoni C, Pino MS, et al. Phase II study of capecitabine and oxaliplatin as first line treatment in advanced colorectal cancer. Ann Oncol 2003,14:1378-82.
14. Makatsoris T, Kalofonos HP, Aravantinos G, et al. A phase II study of capecitabine plus oxaliplatin (XELOX): a new first line option in metastatic colorectal cancer. Int J Gastrointest Cancer 2005;35:103-9.
15. Cassidy J, Clarke S, Diaz-Rubio E, et al. XELOX vs. FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer (MCRC). ASCO Gastrointestinal Cancers Symposium, January 19-21, 2007, Orlando FL: 270.
16. Feliu J, Salud A, Escudero P, et al. XELOX (capecitabine plus oxaliplatin) as first line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 2006;94:969-75.
17. Comella P, Natale D, Farris A, et al. Capecitabine plus oxaliplatin for the first line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer 2005;104:282-9.
18. Twelves CJ, Butts Ca, Cassidy J, et al. Capecitabine/oxaliplatin, a safe and active first line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study. Clin Colorectal Cancer 2005;5:101-7.